Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)

NCT07794670 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT07794670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07794670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
May 31, 2029
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

preclinical alzheimer's disease